ARTV · Insider Trading
Artiva Biotherapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ARTV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | Fred Aslan | Chief Executive Officer | Sell | −23,463 | −$168.88K |
| 2026-10-06 | Subhashis Banerjee | Chief Medical Officer | Sell | −1,099 | −$7.51K |
| 2026-10-06 | Fred Aslan | Chief Executive Officer | Sell | −61,696 | −$421.83K |
| 2026-10-06 | Jennifer Bush | COO, CLO, Compliance Officer | Sell | −8,370 | −$57.23K |
| 2026-10-06 | Christopher Horan | Chief Tech Operations Officer | Sell | −10,340 | −$70.70K |
| 2026-09-15 | Fred Aslan | Chief Executive Officer | A | +110,000 | — |
| 2026-09-14 | Laura Stoppel | Director | A | +16,250 deriv. | — |
| 2026-09-14 | Brian Daniels | Director | A | +16,250 deriv. | — |
| 2026-09-14 | Alison Moore | Director | A | +16,250 deriv. | — |
| 2026-09-14 | Elizabeth L Hougen | Director | A | +16,250 deriv. | — |
| 2026-09-14 | Daniel G. Baker | Director | A | +16,250 deriv. | — |
| 2026-09-14 | Peter Kolchinsky | Director | A | +97,500 deriv. | — |
| 2026-09-14 | Fred Aslan | Chief Executive Officer | A | +45,000 | — |
| 2026-09-14 | Elaine K. Sorg | Director | A | +16,250 deriv. | — |
| 2026-09-11 | Gines Diego Miralles | President & Head of R&D | A | +45,000 | — |
| 2026-09-11 | Christopher Horan | Chief Tech Operations Officer | A | +40,000 | — |
| 2026-09-11 | Subhashis Banerjee | Chief Medical Officer | A | +30,000 | — |
| 2026-09-11 | Jennifer Bush | COO, CLO, Compliance Officer | A | +45,000 | — |
| 2026-09-09 | Fred Aslan | Chief Executive Officer | Sell | −23,429 | −$255.75K |
| 2026-09-08 | Elaine K. Sorg | Director | A | +13,750 deriv. | — |
| 2026-09-08 | Daniel G. Baker | Director | A | +13,750 deriv. | — |
| 2026-09-08 | Laura Stoppel | Director | A | +13,750 deriv. | — |
| 2026-09-08 | Elizabeth L Hougen | Director | A | +13,750 deriv. | — |
| 2026-09-08 | Alison Moore | Director | A | +13,750 deriv. | — |
| 2026-09-08 | Brian Daniels | Director | A | +13,750 deriv. | — |
| 2026-09-08 | Rajeev M. Shah | Director | A | +82,500 deriv. | — |
| 2026-09-04 | Jennifer Bush | COO, CLO, Compliance Officer | Sell | −8,391 | −$93.61K |
| 2026-09-04 | Christopher Horan | Chief Tech Operations Officer | Sell | −10,366 | −$115.64K |
| 2026-09-04 | Subhashis Banerjee | Chief Medical Officer | Sell | −1,100 | −$12.27K |
| 2026-09-04 | Fred Aslan | Chief Executive Officer | Sell | −61,888 | −$690.39K |
| 2026-08-31 | Subhashis Banerjee | Chief Medical Officer | MIXED | −2,916 | −$88.55K |
| 2026-08-19 | Subhashis Banerjee | Chief Medical Officer | MIXED | — | −$4.32K |
| 2026-07-31 | RA Capital Nexus Fund, L.P. | Director | Buy | +274,608 | +$2.73M |
| 2026-07-28 | RA Capital Nexus Fund, L.P. | Director | Buy | +247,914 | +$2.48M |
| 2026-07-23 | RA Capital Healthcare Fund LP | Director | Buy | +39,132 | +$349.84K |
| 2026-07-23 | RA Capital Nexus Fund, L.P. | Director | Buy | +1,587,516 | +$15.50M |
| 2026-07-20 | Peter Kolchinsky | Director | Buy | +962,124 | +$8.59M |
| 2026-07-14 | Rajeev M. Shah | Director | Buy | +129,924 | +$1.16M |
| 2026-06-29 | Rajeev M. Shah | Director | Buy | +197,256 | +$1.75M |
| 2026-06-16 | RA Capital Nexus Fund, L.P. | Director | Buy | +3,187,956 | +$27.60M |
| 2026-06-11 | RA Capital Nexus Fund, L.P. | Director | Buy | +6,166,332 | +$45.90M |
| 2026-05-28 | GC Cell Corp | 10%+ Owner | Buy | +2,864,582 | +$33.00M |
| 2026-05-19 | Jennifer Bush | COO, CLO, Compliance Officer | Sell | −8,790 | −$79.18K |
| 2026-05-19 | Christopher Horan | Chief Tech Operations Officer | Sell | −7,002 | −$63.07K |
| 2026-05-19 | Heather Raymon | SVP, Research and Development | Sell | −3,095 | −$27.88K |
| 2026-05-19 | Subhashis Banerjee | Chief Medical Officer | Sell | −7,037 | −$63.39K |
| 2026-05-19 | Gines Diego Miralles | President & Head of R&D | A | +77,500 | — |
| 2026-05-19 | Fred Aslan | Chief Executive Officer | Sell | −27,116 | −$244.25K |
| 2026-05-13 | Peter Kolchinsky | Director | Buy | +39,062,496 | +$450.00M |
| 2026-03-10 | Thad Allen Huston | Chief Financial Officer | A | +220,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| RA Capital Nexus Fund, L.P. | Director | 17,304,626 | $106.60M |
| RA Capital Healthcare Fund LP | Director | 16,817,543 | $103.60M |
| GC Cell Corp | 10%+ Owner | 5,999,703 | $36.96M |
| Fred Aslan | Chief Executive Officer | 1,519,606 | $9.36M |
| Jennifer Bush | COO, CLO, Compliance Officer | 366,159 | $2.26M |
| Christopher Horan | Chief Tech Operations Officer | 312,744 | $1.93M |
| Peter Kolchinsky | Director | 264,571 | $1.63M |
| Thad Allen Huston | Chief Financial Officer | 220,000 | $1.36M |
| Subhashis Banerjee | Chief Medical Officer | 169,848 | $1.05M |
| Heather Raymon | SVP, Research and Development | 148,228 | $913.08K |
| Gines Diego Miralles | President & Head of R&D | 122,500 | $754.60K |
| Neha Krishnamohan | Chief Financial Officer | 99,356 | $612.03K |
| Thorsten Graef | Chief Medical Officer | 80,000 | $492.80K |
| Rajeev M. Shah | Director | 68,320 | $420.85K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARTV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.